Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Emepronium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed1977

The effects of emeprone on intravesical and intra-urethral pressure in women with urgency incontinence.

By use of a sensitive technique, simultaneous registration of intravesical and intra-urethral pressure changes was performed in 14 patients with urgency incontinence before and after intramuscular or oral administraiton of emeprone. The serum concentrations of the drug at different times after administration were also measured. After intramuscular injection, emeprone caused an increased bladder capacity in all the patients, and they experienced urge at larger bladder volumes. The urethral pressure was little affected. Thus, there were no significant changes of the maximum urethral pressure or of the functinal length of the urethra. Eight out of nine patients got a residual urine. After oral administration of emeprone, two out of five patients got an increased bladder capacity, and experienced urge at a larger bladder volume. They had no residual urine. In the patients receiving emeprone intramuscularly, the maximum plasma concentrations ranged from 1171 ng/ml to 378 ng/ml; they were found after 15 or 30 min. After oral intake, the maximum concentrations ranged from 36 ng/ml to 64 ng/ml and were found after 60 to 180 min. The results suggest that emeprone has actions mainly on the bladder; the effects on the urethra seem to be small.

Administration, Oral↗
PubMed1977

The effects of some anticholinergic compounds on the rabbit ureter.

Atropine, emeprone, and PR 197--a new anticholinergic compound--were examined for their possible effects on the rabbit ureter in situ. Ureteral pressure, recorded at two levels simultaneously, and intravesical pressure were studied. The effects of the substances were recorded in both normal (unobstructed) and obstructed ureters. It was found that all the substances, but especially PR 197, produced a fall in the basic intra-ureteral pressure, which was most pronounced in animals with obstructed ureters. PR 197 also temporarily abolished the ureteral peristalsis, while atropine and emeprone did not have this effect.

Animals↗
PubMed1999

[Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].

Conventional oral pharmacotherapy for urge incontinence remains problematic because of limited efficacy and systemic side effects. In this study 27 patients with severe urge incontinence were treated with intravesical drugs (emepron 200 mg or oxybutynin 5 mg) twice a day. They had previously on average undergone 3.3 other treatment options without satisfactory effect. The average age was 62 years, and their incontinence had on average lasted for 15 years. Seven percent were cured and 41% were improved. Fifty-two percent had no satisfactory effect of the treatment. The number of side effects was low, and none left the study for this reason. Intravesical anticholinergic pharmacotherapy can be a treatment option in women with severe urge incontinence.

Administration, Intravesical↗
PubMed1978

[Conservative drug therapy of neurogenic bladder disorders].

Today neuropharmacas are a helpful part in the conservative treatment of the neurogenic bladder disorders. They are, or course, no "wonder-drugs" and usually lead to an improvement only of the troubles, but rarely to complete cure. If monotherapy does not lead to the results wanted, one should combine drugs of the same of similar effects but with different pharmacologic targets. A real progress was reached through alpha-receptor-blockers, whose use has, especially in children with myelomeningocele, changed the therapeutic concept in favour of a largely conservative treatment. We already know a number of substances that in one way or other influence the muscles of the bladder and the bladder outlet. If only part of them will reach clinical usage, it can be assumed that the pharmacotherapy will become even more meaningful in the treatment of neurogenic bladder disorders.

Adrenergic alpha-Antagonists↗